PBM Reform Is Here: What Self-Funded Employers Must Do Before 2029

The largest pharmacy shakeup in a decade

Three regulatory forces are converging on pharmacy benefit managers simultaneously. The Consolidated Appropriations Act of 2026 mandates 100% rebate pass-through for plans with 100+ employees. The FTC's Express Scripts settlement established precedent for spread-pricing enforcement. And the DOL's new disclosure rule requires drug-level cost reporting that most PBM contracts weren't built to support.

Each rule on its own is manageable. Together they unwind the margin model PBMs have relied on for two decades, and they move the compliance burden onto plan sponsors.

What the new rules require

Self-funded employers with 100 or more covered employees face concrete new obligations starting in 2027, with full enforcement by 2029:

• 100% pass-through of all manufacturer rebates to the plan — retention by the PBM is prohibited.
• Drug-level cost reporting: plans must disclose per-NDC spend, rebate amounts, and net cost annually.
• ERISA fiduciary documentation proving PBM contract terms were negotiated in members' best interest.
• Spread-pricing prohibition: PBMs cannot charge the plan more than they reimburse the pharmacy.
• Penalties of up to $10,000 per day per violation for non-compliant plan sponsors.

Where PBMs will shift the math

PBMs aren't absorbing margin loss — they're relocating it. Expect administrative fee increases of 15–30% as PBMs compensate for lost spread and rebate retention. Watch for new line items: clinical program fees, formulary management charges, and network access premiums that didn't exist in your current contract.

The most sophisticated tactic is rebate reclassification — converting what was previously a rebate into a 'performance guarantee' or 'administrative credit' that falls outside the pass-through mandate. If your contract language doesn't explicitly cover these categories, you'll comply on paper while losing the same dollars under different labels.

You'll comply on paper while losing the same dollars under different labels.

A pre-2029 contract audit playbook

Start now — renegotiating PBM contracts takes 12–18 months, and the enforcement timeline leaves little room for delay:

• Pull your current PBM contract and map every fee, rebate, and spread term against the new CAA requirements.
• Request a full NDC-level claims extract for the last 24 months to establish your baseline cost and rebate profile.
• Compare your net drug costs against NADAC (pharmacy acquisition) and WAC (wholesale) benchmarks to identify hidden spread.
• Renegotiate or RFP before Q4 2027 — contract transitions require 6+ months of data migration and formulary alignment.
• Document your fiduciary process: meeting minutes, market comparisons, and rationale for PBM selection to satisfy ERISA requirements.

How CodaHx helps you verify

Our pharmacy analytics module ingests NDC-level claims and cross-references against NADAC and WAC pricing benchmarks in real time. Employers see exactly where their PBM's reimbursement rates diverge from market pricing — by drug, by pharmacy, by fill.

Rebate pass-through tracking surfaces the gap between reported rebates and manufacturer-published WAC discounts, so you can verify compliance without relying on the PBM's self-reporting.